3mnl

2025 is expected to be a transformative year for data science professionals, as the demand for skilled talent will soar across various industries. Companies are increasingly recognizing the importance of data-driven decision-making, resulting in numerous career opportunities in this dynamic field. If you aspire to advance your career in data science, this guide highlights the leading companies for data scientists and the most sought-after job positions they offer. Leading Companies in Data Science Accenture stands out in the business and consulting sector for its commitment to leveraging data science to address complex business challenges. The company provides diverse opportunities for professionals to work on AI, data engineering, and machine learning projects. This focus on innovation makes Accenture a preferred choice for those seeking career growth in data science. Deloitte is renowned for combining data science with strategic insights to drive innovation across multiple sectors. Data scientists at Deloitte work on projects ranging from financial analytics to healthcare solutions, making it a sought-after workplace for professionals eager to make an impact in varied industries. TCS, a leader in software development, offers significant Data Science Career Opportunities. The company employs data scientists to enhance its IT services and deliver AI-driven solutions for global clients. TCS’s focus on digital transformation ensures that data scientists play a critical role in shaping its offerings. IBM’s emphasis on AI and cloud technologies creates a steady demand for data scientists. IBM professionals have the chance to work on advanced projects involving machine learning, AI integration, and innovative cloud-based solutions, making it an exciting option for those looking to work at the forefront of technology. Infosys leverages data analytics to optimise business processes across industries. Its data scientists contribute to projects that drive efficiency and innovation, offering ample opportunities for growth in the field. Tech Giants and Innovation Leaders Microsoft’s heavy investment in AI and cloud computing makes it a top employer for data science professionals. Microsoft data scientists work on groundbreaking technologies that shape the future of AI-driven applications and big data analytics, ensuring exceptional career growth. Amazon’s operations in e-commerce and cloud computing rely heavily on data-driven insights. Data scientists at Amazon tackle complex challenges in logistics, customer behavior analysis, and recommendation systems. This makes Amazon a leading destination for data science talent. Oracle offers exciting roles in data science through its focus on database solutions and cloud platforms. Data scientists here work on integrating analytics and AI technologies into its services, enhancing the capabilities of its global offerings. Nvidia is at the forefront of AI and machine learning innovation. The company employs data scientists to develop hardware and software for cutting-edge deep-learning applications. Nvidia’s role in advancing AI makes it a top choice for those passionate about technological innovation. Insights into Data Science Career Opportunities The job market for data scientists is expanding rapidly, with millions of new positions expected globally by 2026. This growth is driven by the increasing adoption of AI, machine learning , and big data analytics across industries. Companies are actively seeking professionals skilled in these areas to gain a competitive edge in their respective markets. Consulting firms like Deloitte and Accenture often lead in offering high-paying roles, while tech giants such as Amazon and Microsoft provide unparalleled opportunities to work on transformative projects. A Data Science career not only offers financial rewards but also opens doors to exciting and impactful work. Why Pursue Data Science in 2025? Users require talents in analyzing data and trends, such as in IT, health care, finance, and retailing, to mention but a few. With increasing importance afforded to analytics decision-making, data scientists are strategically positioned within organisations. The field provides new directions in roles like designing and deploying AI solutions and building predictive analytical models, so the work is quite stimulating. Data science is also universal, meaning that those in the profession can secure jobs anywhere in the world. Organizations appreciate professionals who can utilize big data to increase productivity, create more value, and gain competitive advantage. Conclusion The demand for experienced data scientists is expected to remain high in 2025. Leading employers in the field, such as Accenture, Amazon, and Microsoft, will continue to recruit talent. This creates a variety of roles and excellent opportunities for career advancement, making a career in data science particularly appealing. Through ongoing personal development, aspiring data scientists can look forward to lucrative careers in this rapidly growing industry. It is now possible to secure some of the highest-paying data scientist positions and build a successful career in data science.A lack of rules to help keep aging drivers — and you — safer on the streets causes serious, even fatal, consequences, Scripps News Cleveland found in a recent investigative report. So-called "mature drivers" (55+) were the most common variable in Ohio motor vehicle crashes over the last six years. State records show mature drivers were involved in 525,290 crashes between Jan. 1, 2019, and Nov. 12, 2024. The number of crashes involving mature drivers was higher than youth-related crashes and speed-related crashes. Despite those numbers, Ohio and other states have no special provisions to ensure older drivers are safe behind the wheel. Ignoring the risk "We really, as a society, mostly ignore it," said Sharona Hoffman , Case Western Reserve University, School of Law, and author of "Aging with a Plan: How a Little Thought Today Can Vastly Improve Your Tomorrow," which provides resources to help middle-aged and older adults deal with all aspects of aging, including driving. "There is not a good legal framework that tries to identify unsafe driving and address it," she said. Ohio is one of 13 states that does not have any regulations aimed at aging drivers on the roadways, according to the Governors Highway Safety Association. Other states have only enacted minor provisions, including more frequent license renewals and vision tests and requiring drivers to renew their licenses in person instead of by mail. Nevada and Washington D.C. require a doctor's note for drivers over 70. Only Illinois requires drivers to take another road test after they turn 75. Hoffman said driving decisions are mostly left to families. "Doctors often don’t get involved in that and so it’s up to families, and that can be extremely difficult," she said. Hoffman said older drivers often "don't want to hear they are a hazard," and families are often reluctant to engage in difficult conversations with loved ones about driving. At the same time, more older Americans are driving. The most recent Federal Highway Administration estimate is that there are over 34 million licensed drivers who are 70 or older in the U.S. 'If I wasn't there...' Even serious incidents can have little or no impact on an aging driver's license. Over the summer, Newburgh Heights Patrol Officer Russ Veverka was working his regular overnight shift on Interstate 77 when one car caught his attention. The driver was headed northbound in the southbound lane. At the same time, several vehicles were approaching from the opposite direction. "The one thing I’m not going to have is another vehicle hit head-on with another vehicle in front of me," he said. "I don’t think I could handle that at all." So from a grassy knoll near the Harvard Avenue bridge, Officer Veverka activated his overhead lights and drove onto the highway, blocking a lane. The driver saw him and stopped. The driver turned out to be a 65-year-old man who had been reported as a missing endangered adult earlier that day. A 4-year-old relative was standing in the backseat with no restraints. "Seeing that, my heart wanted to drop," Veverka said. The driver appeared confused and kept saying he was on Interstate 480. He had been driving around with the little boy for hours. After stopping the wrong-way driver, Veverka submitted form 2308 to the Ohio Bureau of Motor Vehicles to request the driver take a road test. "That's the best we can do right now," Veverka said. But when Scripps News Cleveland reached out to the driver's wife, she told us nothing had changed. She said her husband is still driving, including picking up the 4-year-old boy from daycare. Jackson Township tragedy "We all have family members that we think, 'Eh, maybe they shouldn't be driving," said Jackson Township Fire Chief Tim Berczik. His department recently started outreach efforts to older drivers after reviewing the city's crashes over the last year. He found mature drivers were involved in eight fatalities in the city of approximately 44,000 residents, including a crash that killed a 69-year-old grandfather in October. Berczik said an 81-year-old woman crashed into Angello's 2 Go pizza shop when she accidentally hit the gas pedal instead of the brake pedal in her car. His staff is now showing older drivers how to stay safer in their vehicles, including proper seat and mirror placement. They also encourage anyone with concerns to be retested. "We're not talking in any way about, 'We need to take car keys away from senior folks,'" he said. "Make it a group decision that maybe we don't drive as much." He said mature drivers can limit the distances they drive, stop driving at night, or stick to familiar areas to keep themselves and others safer on the roads. 'Life is for the young..." Handing over your keys carries its own consequences. "We live in a society where our autonomy often depends on driving," Hoffman said. "They won’t be able to go to doctor’s appointments as easily, and they can become socially isolated, which is catastrophic for anyone, but especially older people." "If you are lonely, if you are not engaging with other people, that is a sure recipe for cognitive decline and other physical and mental health problems," she said. In a recent law review article, "Patient Autonomy, Public Safety, and Drivers with Cognitive Decline ," Hoffman and her co-author recommended doctors be required to send patients diagnosed with cognitive decline and other conditions for road tests. Right now, medical professionals are only encouraged to notify the Ohio Bureau of Motor Vehicles about their concerns about a patient's driving. However, Scripps News Cleveland found only 18% of those drivers lost their licenses. Hoffman also said law enforcement officers should be trained to identify cognitive decline and report problem drivers. "I've had relatives who've driven into mailboxes, lamp posts, and parked cars and each time they have just gotten a warning or a ticket," she said. 76-year-old Brook Park resident Rose Ramsey said she isn't as confident in her driving skills as she used to be. "Once in a blue moon, I kind of forget the route that I was going," she said. "I'm planning on going a certain place and then I just kind of have to let the car lead the way." When she is worried about taking the wheel, she relies on her husband of 56 years, Kenneth. "I have my own chauffeur," she said. She supports requiring drivers to be retested as they get older. "John Q. Public and myself needs to be safe," she said. Ramsey said she knows that means she and her husband will eventually have to give up their own car keys. She admits it will not be easy. "I know it would be very difficult for us and yet I do understand that time is coming," she said. "Life is for the young, isn't it?" What should you do? If you're concerned about a loved one's driving abilities, Hoffman and Berczik both recommend the following: This story was originally published by Sarah Buduson at Scripps News Cleveland .Wanjigi tells Kenyans to start tax revolution3mnl 。

Unlocking Gaming’s Future! The Surge of Nvidia Stock in 2023As 21-year-old Nitish became the third youngest Indian to score a maiden Test ton in Australia, legendary Sunil Gavaskar was left impressed with the feat, as he was seen gaving a standing ovation to the young talent the commentary box. ET Year-end Special Reads Take That: The gamechanger weapon's India acquired in 2024 10 big-bang policy moves Modi government made in 2024 How governments tried to rein in the social media beast "Wonderful wonderful shot that. Straight bat and lofted shot to get to his first hundred. And I am pretty certain that this is going to be the first of many hundreds. What a find this man has been for Indian cricket. Superb innings, fantastic temperament. A great mix of talent and temperament. Fantastic stuff, young man. Keep going. Keep going!," said Gavaskar as he clapped for Reddy on-air. — abcsport (@abcsport) Nitish Reddy , an unknown entity in red ball cricket before the start of Border-Gavaskar series, virtually bailed India out with his dogged maiden Test century here on Saturday, severely denting Australia's hopes of winning the Boxing Day contest. Reddy's unbeaten 105 took India to 358 for nine, still 116 runs short of Australia's first innings score of 474 as rain brought an early end to the third day's play. With the flat MCG deck not offering much to the bowlers, saving the Test match shouldn't be a big deal for India. Reddy, easily India's 'find of the series', played a pivotal role in visitors' fightback. Reddy's combative spirit and the invaluable 127-run stand he shared with Washington Sundar (50 off 162 balls) proved to be the turning point for the hosts. Reddy's innings was termed as one of greatest Test knocks by the legendary Sunil Gavaskar given the situation as India were in a precarious position after Rishab Pant's dismissal courtesy a rash shot had left India tottering at 191 for six. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program The young Andhra batter could have been stranded on 99 when Jasprit Bumrah got dismissed, leaving Reddy with last-man in Mohammed Siraj, who walked in to another round of boos and faced three deliveries from home skipper Pat Cummins. Both Reddy and his father Muthyala's expressions changed with each ball but Siraj survived to allow Reddy savour the moment he must have dreamt a thousand times. The 21-year-had struck the 'Pushpa' pose after completing his fifty and aced the 'Salaar' pose to celebrate the century. Reddy has been by far India's most consistent batter in the series and the maiden Test century couldn't have come at a more opportune time and that too at an iconic venue. (You can now subscribe to our Economic Times WhatsApp channel )

Guess which ASX copper stock could be the best to buy nowThe No. 1 UCLA women’s basketball team digs deeper into its first season of Big Ten Conference play Sunday against Nebraska and continues Wednesday with No. 23 Michigan. The preparation, however, has been underway for much longer. “The work done in the dark always gets revealed in the light,” head coach Cori Close told reporters. “And we’re about to step into a lot of bright lights. It will be truly the things that will be behind the scenes that lead to us doing really, really well when the bright lights come on.” Close disclosed after Dec. 20’s 70-41 win over Creighton that the coaching staff and players are now watching film from up to 11 games on Big Ten opponents as opposed to the six or seven games that they watched for Pac-12 opponents prior to changing conferences. Playing each conference opponent once has doubled the workload for scouting, which has garnered heightened emphasis for the No. 1 Bruins (12-0 overall, 1-0 Big Ten) “We have a video team that’s not only double the people looking at analytics and we have multiple people doing video breakdown before it ever gets to an assistant coach,” Close said. “The toughest, more together team wins. But you can’t execute that unless you’re extremely prepared.” It’s unclear if 6-foot-7 center Lauren Betts will be a part of UCLA’s preparation this week. Betts, who is averaging a double-double this season, hasn’t played in a game since defeating Long Beach State 102-51 on Dec. 14 and is day to day with a leg injury sustained in that game. “Teams that are smaller than us – I get it, we have a huge advantage,” she told reporters after a 69-37 victory over Cal Poly . “What cannot be allowed is taking our players out at the legs. That’s the reason that Lauren Betts is out today is because of a play that was like that.” Sunday will mark the Bruins’ first game since Dec. 20 and the Cornhuskers (10-2, 1-0), who are receiving votes in the AP Top 25 poll, will feature a more competitive size matchup with eight players who are over 6 feet tall. It’ll be Nebraska’s second straight game against an unbeaten opponent after the Huskers lost to then-No. 17 Georgia Tech on Dec. 21. Forward/center Alexis Markowski recorded her fifth double-double of the season and 45th of her career by logging 20 points and 10 rebounds in the game. Michigan heads to No. 4 USC on Sunday before Wednesday’s game at UCLA. The Wolverines had their first conference game Dec. 8 when they beat Northwestern and have three freshmen averaging double figures in scoring in Syla Swords (15.3 ppg), Olivia Olson (15.7 ppg) and Mila Holloway (10.8 ppg). The Bruins have a deep, versatile roster to rely on even if Betts isn’t healthy enough to play Sunday. Freshman Elina Aarnisalo leads the team in total minutes played with 310 and in assists with 5.3 per game. UCLA shares the ball well, with seven players averaging eight points or better per game. The Bruins are the top team in the Big Ten in assists with 20.6 per game. Related Articles “This is one of the most exciting parts of the season – getting into conference play knowing that every single night we go out there we’re going to have a really good competitor on the other side,” Rice said. “That’s what we train for and we’re looking forward to that.” When: 2 p.m. Sunday Where: Pauley Pavilion TV/radio: Big Ten Plus/UCLA Digital Radio When: 2 p.m. Wednesday Where: Pauley Pavilion TV/radio: Big Ten Network/UCLA Digital Radio

Kalyan Girl Rape-Murder Case: Senior Advocate Ujjwal Nikam To Represent Case in Court, Announces Maharashtra CM Devendra Fadnavis

1. The super sleek Oura ring , which connects to their smartphone to help monitor their sleep, heart rate, and various fitness goals. It's much more subtle than a bulky smartwatch, so they won't mind keeping this on 24/7. Heads up: The brand recommends buying the Oura sizing kit for $10 first to figure out which size works best — so you might want to gift the kit now to figure out the sizing! Either way, you'll get a $10 credit back for the purchase of an Oura ring! Promising review: "First of all, I love it and never leave reviews. But this needs justice. It looks like a regular ring; nobody would be able to tell the difference. The sleep tracking is super accurate, showing REM, light, and deep sleep, plus heart rate and temperature. The subscription is $6 a month, which is completely worth it, in my opinion. You get detailed info on stress, recovery, and even tips for staying in sync with your body’s natural rhythm. It’s lightweight, water-resistant, and comfy enough to wear 24/7. I never take it off. It charges extremely fast, and the battery life is amazing—I only charge mine once a week." — Ethan A. Get it from Amazon for $349 (available in sizes 9–15 and six colors). 2. A magical pen so they can bring their artwork to life in 3D! It's like Harold's purple crayon, except this hopefully won't get a terrible live-action version starring Zachary Levi. Aspiring artists can load the pen with one of the included colored sticks (they're made of plastic filaments), then press the button to release the moldable plastic and create a 3D masterpiece. Their parents might just want to get in on the fun, too! The kit includes the pen, two refill packs, an activity guide, USB cable, and a doodle pad. Promising review: "I will be the first to admit that I thought this was going to be a novelty toy that my kids used once (then it would fall by the wayside). I mean, it’s basically a glorified glue gun! To my amazement, my kids can’t get enough of it. They fight over it. They use it every single day. To be fair, there is no way a kid can make anything like the examples on the box. I realize their projects aren’t going to make it into a fine art gallery, but it keeps them busy and creative. They fix toys with the doodler and are convinced it is a magical tool that can solve any problem. I never imagined I’d be giving this 5 stars, but whoever thought of this device is a genius (and clearly knows kids better than me!) " — Casey C. Get it from Amazon for $32.99 . 3. A pair of AR sunglasses , which is basically a personal wearable TV screen only they can see. It connects to their smartphone, tablet, or laptop so they can see a projected version of the display through the glasses without having to look down. Their neck will be so grateful. It includes buttons to control brightness and focus levels. This works with most USB-C devices right out of the box, though an adapter will be needed for iPhones with lightning ports. Promising review: "I loved my first pair of VITURE glasses, but the latest iteration has blown me away! The image on the screen is even better than the original and I feel like you can really tell a difference at the edges of the screen. I’ve used them for hours at a time and have found them to be exceptionally comfortable. They have definitely helped with neck and back pain from looking down while working with a laptop in my lap. I also find them to be a great option when I need to work on a plane. I avoid the painful and awkward neck gymnastics when I try to work without them because I no longer have to lean down to try to see the screen that’s canted at a weird angle because of the seat in front of me. Another bonus is the privacy they afford while working in crowded public spaces." — James Get it from Amazon for $499 . 4. A digital notebook they can use again and again. The LCD display acts just like normal paper when they use the included stylus, so they can write to-do lists or doodle whatever creation pops into their head. Once they're done, they can hit the "erase" button to clear the "page." It's basically like an adult version of a Magna Doodle, except they won't be embarrassed to use this in a meeting. Promising review: "The boogie board is a great tool for anyone looking to save on paper while jotting down quick notes. It’s wonderful for quickly writing and erasing math problems, shopping lists, or anything in between. It’s also super affordable, making it a cute and cost-effective gift for any age." — Bradley Get it from Amazon for $16.99 (available in three colors). 5. Or a Rocketbook reusable notebook that lets them take notes they can save digitally, erase, and then use all over again. They can use the Rocketbook app to save all of their "pages" and then erase them with the included wipe. You're essentially gifting them an endless notebook. Promising review: "I am very happy with my purchase of the Rocketbook. I have it set to the side on my desk for quick scribbles when I need to make notes. It has eliminated a bunch of messy scrap pieces of paper all over the place. The pen that came with it works great (I am fussy about that); it feels like normal pen to paper. When I'm done, I just spray a bit of water and wipe clean. Great organizational tool and keeps my office neat and free of extra clutter ." — KMS Get it from Amazon for $36.13+ (available in three styles and 17 colors). 6. A high-tech planter pot for the green thumb on your list who has trouble keeping track of their plant children. The adorable display on the front lets them know how happy their plant is (i.e., if the soil is moist enough and if it's getting enough light), and it even has a self-watering feature they can control through the smartphone app. This is basically a grown-up Tamagotchi. Promising review: "I got this as a gift, and they love their Ivy planter! The digital expressions are cute and adorable, but aside from that, the size and quality of the planter itself make this an excellent planter. The app it comes with is easy to use and makes it easy to take care of your plant. I look forward to getting this for myself in the future!" — Mario Get it from Amazon for $75.04+ (available in five colors). 7. A gorgeous water bottle that keeps track of their daily water intake and glows when they're running behind on their hydration goals — because we could all use some help being a little less thirsty. It even connects with a smartphone app so they can have a snapshot of their weekly hydration habits. Promising review: This is the most amazing water bottle ever! I don’t drink water, I don’t like water. I have a health condition that requires me to drink 60+ ounces of water a day. This is coming from a person who drinks one glass of water every two weeks. When my doctor told me I had to drink 60+ ounces of water a day, I was literally freaking out. I didn’t know how to do it! So I started searching water bottles that will track what you drink because otherwise I wouldn’t know how to track my water intake. When I found this bottle, I thought, okay, I’ll give it a shot and see how it goes. It literally has changed the way I drink water. Getting on the app and connecting to the bottle was super easy. The bottle tracks your water intake, and if you’re not drinking enough, it will light up to remind you that you need to drink water. I’m really busy during the day, and most of the time, I don’t drink water, and I sure as heck don’t pay attention to my water intake. The light up reminder, which is really neat, and you get to select the color, makes you very conscious of needing to drink." — Amazon Customer Get it from Amazon for $49 (available in four colors). 8. Or a self-cleaning water bottle — it uses a UV-C LED light in the cap to help purify water and keep the inside clean. Tap the button on the top to activate, and then it'll run a cleaning cycle every two hours to keep things clean and fresh. The insulated design keeps drinks cold for 24 hours and hot for 12 hours. Promising review: "Yes, this bottle is pricey, but having purchased it for travel, I found it very comforting knowing whatever water source I was filling up from, my water would be clean due to the interior UV sanitizer. And I actually saved money instead of buying tons of plastic water bottles for a month-long trip. Highly suggest the insulated bottle, as I purchased the slightly cheaper non-insulated bottle as well, and although lighter, preferred the contents staying nice and cool while traveling through the summer." — Mike L. Get it from Amazon for $99+ (available in two sizes and seven sizes). 9. A smart bird feeder with a camera inside so they can see all the delightful visitors who stop by for a snack. It connects to the accompanying smartphone app and can send them an alert when a bird has appeared so they can see a live feed of their new flying friends. They can also save videos and photos, so be prepared to see so many bird pics on their Instagram story. Promising review: "The bird feeder is easy to assemble and very easy to set up. The motion detection is just the right amount and reliable. I enjoy getting notifications of birds at my feeder. The product is durable and not cheap feeling. This feeder brings a lot of joy to my day. It's easy to share your videos with friends, so many of my friends get to enjoy it as well." — Robert F. Get it from Amazon for $149 (available in two colors). 10. A pet camera that adds a distinctly 2024 upgrade: they can play with their pet via a smartphone app! The app lets them control a laser pointer so their ball of fluff can tire themselves out and get some mental stimulation even when their hoomans aren't at home. This is the future Nintendogs promised!!! Promising review: "I didn’t know what to expect when I got this as far as quality of video or laser toy or connectivity away from the house. All I can say it has far surpassed my expectations in every way. Let me give you an example. I was on my way down to the ground on a plane. I thought, let me check on my cat. Using the Wi-Fi on the plane, I was able to access the video feed in my home living room and see my cat was there bored and needing to play. I enabled the laser toy and proceeded to play with her for five minutes while we finished landing. She had a great time and I was reassured she was ok. The quality of the video was great, almost no lag, and the laser toy worked like a charm! There is a little lag for the laser toy but it still is great. A+ for this. I would gladly recommend to anyone." — B. Mann Get it from Amazon for $79.99 . 11. A pair of smart goggles I bet even Michael Phelps would be impressed with. The display on the inside displays their heart rate, time, distance, stroke count, and pace — and they can connect them to the accompanying app to keep track of their workouts. Note: This requires a $99/year subscription service to access guided workouts and a digital compass. Promising review: "I’ve been using the goggles for the past few weeks, mostly in the pool. The goggles capture everything I need (i.e., heart rate, stroke rate, and pace) without having to wear a sports watch. Accuracy and reliability for heart rate are impressive. I train with HR while running, so it’s nice to bring this approach to the pool." — Elliott Get it from Amazon for $249. 12. A spinning ball decked out with LED lights that flies around on its own. They can channel their inner Doctor Strange and make it hover over their hand, or they can throw it and watch as it boomerangs back to them. I don't know how they managed to make a ball futuristic, but I tip my hat to the designers. Promising review: "You control where this flies by the tilt you put into when releasing. Really fun to play catch with someone by tilting it toward them and gently releasing. You can also boomerang it back to yourself by tilting it backwards and tossing it up diagonally away from you. The cage around it is effective in protecting both you and it." — Dem Get it from Amazon for $28.80+ (available in seven colors). 13. A five-panel clock that looks straight out of Blade Runner . It features five small screens that can be customized to display everything from the time (duh) to the weather and stock market performance. The accompanying app even lets them create pixel art to display on the screen if they're feeling creative. Promising review: "I was skeptical before buying this thing but it actually works really well. There is tons of pixel art you can download and display and it can do really cool, useful stuff like show you the weather or stock prices, too. I'm a huge fan!" — Trevor Get it from Amazon for $113.99+ (available in two colors). 14. A USB fan with an LED clock face that looks like it's levitating in the air, which will make everyone in the office stop in their tracks when they walk by their desk. It also displays the temperature, so they can basically go ahead and delete the Weather Channel app from their phone. Promising review : "Fun at work. I got one of these for my husband at his office. Now EVERYONE has one at his office, including me at home!" — Laurette Triick Get it from Amazon for $15.99 . 15. A UFO-shaped Bluetooth speaker that hovers and spins around while playing all their favorite alien-themed podcasts. Functional and a conversation starter? This is guaranteed to win you some major points with that one family member who is just a little too obsessed with extra-terrestrial beings. ~Cute the X-Files theme song~ Promising review: "I wanted this mostly cuz I thought it looked really cool! It was pretty easy to set up and was going in no time! Everyone that sees it wants one and I am already on my second order! For a small speaker it has decent sound as I am using it for background noise and don't want it loud. It does, however, go up to a nice volume! It is very cool, and I'm so glad I bought one...well two now LOL!" — Karen Get it from Amazon for $99.99 . 16. A mirror with features every mirror should have in the future: built-in lighting, a Bluetooth speaker, and an anti-fog button. If they seem a bit more chipper in the morning than usual, it's because you just massively upgraded their routine. Promising review: "This thing is absolutely neat as all can be, hands down. I've seen the other ones, but this one has JUST enough functionality to make it cool and modern, but not so much that it is fully IOT/Wifi connected, and you have to worry about it potentially spying on you. I love the Bluetooth speaker functionality and the defogging/backlight. I love that this doesn't need to connect to Wi-Fi, doesn't require an app, and just WORKS out of the box, with no fiddling around . For the price, I think I'm going to get a few more of these for my other bathrooms. Wonderful job on this." — Mike Get it from Amazon for $109.99+ (available in nine sizes and three shapes). 17. An electronic upgrade to the classic Rubik's cube , which I strongly feel Elroy Jetson would play with all day long. It features four different games to choose from, or they can choose the "light show" setting to enjoy the glow from the colorful lights once their brains are too tired to play anymore. Promising review: "This little dude is a lot of fun for sure. It keeps my brain occupied and my fingers moving when I can't sit still. Not to mention, the music that plays in the menu is a certified BOP. My only tiny criticism is that the buttons are a tad too stiff when pushing on them, though; I suppose that's a good thing when you're twisting it around in your hands, and you don't accidentally push a button and ruin your score. I love the mute feature during gameplay." — Jennifer Get it from Amazon for $24.99 . 18. A super sleek lamp with a small globe that ~magically floats~ in the air — and it will even spin for up to 20 minutes if they give it a quick tap with their finger. I suspect all lamps in the future will feature some sort of gravity-defying feature. Promising review: "Globe is lightweight. This is a great thing to gift someone. It's fun to watch spin, and the light in the back is beautiful. It doesn’t spin on its own; you have to gently spin it, but once you start it, it lasts for quite a while." — Emilly Get it from Amazon for $32.39+ (available in three colors). 19. An app-controlled moon-shaped dock that functions as a lamp, wireless charger, and a bluetooth speaker because the future is truly all about multiuse products and saving outlet space. I suspect this is what Zenon uses to charge her SpacePhone and listen to "SuperNova Girl." Promising review: "The vibrant colors of the lamp look really beautiful!!! The speakers and the lights that dance to the beats are perfect for a mini disco atmosphere . It works great as a bedtime lamp for my bedroom, and the app is really convenient to control the light and music (white noise included!). This is a fun gadget for my teens. I give 5 out of 5 stars, satisfied." — Vanshika Sharma Get it from Amazon for $46.99 . 20. A smart meat thermometer — it will basically be their very own personal electronic sous chef. It connects to the Meater app to help configure cooking times and tell them the temperature right on their phone. The days of continuously opening the oven door to check on their roasted meats will be far behind them. It works for meats cooked in the smoker, grill, rotisserie, oven, pan, and air fryer! Promising review: "The Meater works so well, you hardly have to do anything while you cook any sort of meat. Once it alerts you the meat is ready, you remove it from any heat, and when the app says you’re ready to dig in, there’s no second guessing whether or not your meat is fully cooked. No under/overcooking with this; it’s perfect EVERY time. Couldn’t be more happy with this product and app." — Pam Walter Get it from Amazon for $79.95 . 21. A "Worky" station , the on-the-go desk they never knew they needed. Once they unfold the suitcase-style design, they'll have plenty of space for their laptop and office supplies, and there are even USB ports to charge their devices. Perhaps best of all, the top portion (which also functions as a whiteboard!) has LED lights, so they'll be in perfect lighting for all of their Zoom meetings. This is truly the ultimate gift for the remote workers on your list. Check out a TikTok of the Worky station in action. Promising review : "I've had my Worky for three months now and have loved it. I love that everything is in one place, and then I can close it up and work disappears. The compartments are great for tucking away piles of paperwork, the multiple charging outlets are convenient, and the LED lights are helpful on Zoom calls when lighting in the room is not ideal. Everything in one place, simple and convenient. Just the way I like it." — Amy Worky is a small business that specializes in products to improve remote working experiences. Get it from Amazon for $119.99 . 22. A Bitzee — it puts a 3D spin on the traditional virtual pet from our childhood. Simply open the capsule to reveal one of 15 pets that respond to touch, tilts, and swipes. There's even a Disney version with characters like Stitch, Wall-E, and Lightning McQueen! When their pets evolve into Super Bitzees, they can find cool outfits and mini-games. In a rare turn of events, batteries are included! Promising review: "My 8-year-old loves this thing so much that she hasn't put it down since she got it. It was the star of the show for Christmas, and I got so many hugs for getting it for her. This is basically the modern take on the old-school Tamagotchis, but it has a fluttering LED bar that zips up and down at an extremely high rate of speed to mimic the appearance of an actual digital pet floating in midair. Seems weird at first, but that fluttering light bar also allows you to feel like you are really touching the animal — very cool in action. If you are a parent looking for the perfect gift for a 5-10-year-old child, then do yourself a favor and grab one of these; you will not regret it! Really awesome toy for a very reasonable price." — M. Myers Get it from Amazon for $24.49+ (available in four styles). 23. A hybrid digital food scale and measuring cup which is some next-level baking tech even Paul Hollywood would be impressed with. Now, they can accurately measure all their ingredients directly in the cup, and they can also use the handle attachment as a stand-alone food scale. Promising review : "I absolutely love this measuring cup!!! What a great invention. I love that I can put flour in, reset it and add sugar, reset it and add milk, etc. One cup for measuring several things at the same time. Love, love, love it!!!!" — wolfpause Get it from Amazon for $18.99+ (available in three colors). 24. A touchscreen toaster to replace the crusty one they've had in the kitchen for longer than they'd like to admit. It heats much faster than a traditional unit and has a touchscreen that lets them choose their preferred level of crispiness. This is the future carb connoisseurs want. So why does a toaster need a touch screen? Because this one has some impressively specific toasting options for their carb of choice. It features fresh, frozen, and reheat options, and they can swipe between bagels, toaster cakes, English muffins, waffles, and bread. They'll probably text you "thank you!" every morning for gifting them with perfectly toasted bagels every time. Promising review: "I have to say, this toaster was well worth the investment. This one beat my old toaster by a mile in terms of how fast it toasts, and it adjusts easily and well to waffles and bagels. The toaster has a fantastic digital display, too. I love the 10-second countdown feature so I can get my butter in place and slather it on while the toast is hot. The design is sleek and elegant, and my favorite surprise is the analog clock display. This makes my old toaster obsolete (it's now collecting dust in the bottom cupboard)." — Rob Get it from Amazon for $299.95+ (available in two colors and with various accessories). 25. A fancy smart mug that will keep their coffee, tea, or other hot beverage of choice at the perfect temperature. It lasts for 90 minutes on a single charge, and if they have enough self-control to make a cup of coffee last longer than that, I simply cannot relate. Promising review: "Best thing since sliced bread! I hate it when my coffee gets cold. I was originally looking for one of those warming coasters, but then I saw the Ember mugs...there was no turning back. I can take my coffee with me into my boss's office, and it still stays hot?? Yes, please. I used that app and have adjusted my temp down to 127 degrees. It stays at that temperature the entire time. I’ve not had an issue with battery life either; it doesn’t take me more than an hour to polish off a cup of coffee. I HIGHLY recommend." — Mathews Get it from Amazon for $92.62+ (available in 11 colors). 26. Oral-B's Genius X Limited electric toothbrush equipped with AI that adapts to their unique brushing style so they can ensure they're getting a deeper clean. It even connects to their smartphone to help keep track of their daily brushing habits. Promising review: "Amazing clean. I was at first hesitant to spend that much on a toothbrush, but it’s worth every penny. It works at least 10x better than my $20 Oral-B electronic toothbrush. The motion sensing is very cool and helpful. After just one brush, my teeth feel almost like they do after a professional cleaning as opposed to how they felt after brushing with my cheap electronic toothbrush. " — Anne E La Perla Get it from Amazon for $190.31+ (available in three colors) 27. A fingerprint padlock so they'll never have to rummage around in their pocket looking for their key before realizing they left it at home. This also connects to a smartphone app if they prefer to control it remotely. Promising review: "This is a superb lock! I got it to use in the gym. I didn't want to use the honor system and hope my locker would be safe without a lock... and I know I am not the best with traditional combo locks. This lock does everything you need. It's easy to set up as many fingerprints for verification as you want ... and you can even just use your phone to unlock it alternatively." — J Z D Get it from Amazon for $36.99 (available in two colors). Reviews have been edited for length and/or clarity.None

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL- ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI ® . Initiate treatment with TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI ® until CRS resolves or permanently discontinue based on severity. Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious and life- threatening reactions, can occur in patients receiving TECVAYLI ® . Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI ® until neurologic toxicity resolves or permanently discontinue based on severity. TECVAYLI ® is available only through a restricted program called the TECVAYLI ® and TALVEY ® Risk Evaluation and Mitigation Strategy (REMS). INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . Media contacts: Sarah Freeman sfreem21@its.jnj.com Christie Corbett ccorbet6@its.jnj.com Investor contact: Lauren Johnson investor-relations@its.jnj.com U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-302325575.html SOURCE Johnson & JohnsonIt’s, quite literally, the end of an era for Taylor Swift . That’s right. After more than 150 performances around the globe, the 34-year-old is making the whole place shimmer one last time during the final stop on her Eras Tour in Vancouver, Canada, Dec. 8. And while the “Bejeweled” singer has commanded the attention of millions of fans both in-person and online throughout the world tour’s nearly two-year tenure, her unparalleled performances have also caught the attention of today’s biggest stars—including her boyfriend Travis Kelce . But celeb sightings are nothing new at The Eras Tour . Recently, Taylor’s longtime BFF Blake Lively attended the “Cruel Summer” singer’s concert in New Orleans with husband Ryan Reynolds . And based on the Deadpool actor’s rave review on social media, it’s safe to say he had the time of his life. “When I’m 95 yrs old and my wife and kids wheel me outside and into the sun so I can drink a sandwich, I’ll still be talking about seeing this show in New Orleans ,” the 48-year-old wrote on Instagram Oct. 31 . “Not just because it’s one of the best things I’ve seen/heard/felt. And not only because you see the staggering and positive economic impact this tour has on small businesses all over NOLA — a town that’s been thru so much for so long.” Ryan—whose oldest daughters with Blake, James , 9, and Inez , 7, even joined in on the fun during their godmother’s concert in Madrid—continued, “The main reason I’ll never forget this show is because it brings people together in so many ways. And in 2024, (where that feeling is scarce as hell) it’s a special and incredibly rare thing.” Indeed, the Eras Tour has brought together its fair share of celebs at every stop across the globe. Serena Williams was amongst the stars that showed up and showed out for Tay at the Oct. 18 show in Miami. The tennis legend had a fun night out with her daughters Olympia , 7, and Adira , 15 months—who she shares with husband Alexis Ohanian —and the trio even matched in sparkling Eras-approved outfits. That same weekend, Tom Brady enjoyed a boys night with his sons Jack , 17—whom she shares with Bridget Moynahan —and his and ex-wife Gisele Bündchen ’s son Benjamin , 15. And, of course, since her romance with Travis began, Taylor’s performed in front of the Kelce family. In Miami, Travis’ brother Jason Kelce and his wife Kylie Kelce —who previously went to her London shows—brought their elder daughters , Wyatt , 4, and Elliotte , 3. (Rest assured, Travis and Jason’s parents Donna Kelce and Ed Kelce have also cheered on Taylor at her shows.) But that is just the tip of the iceberg when it comes to Taylor’s famous fans. For more stars who have been spotted at The Eras Tour, keep reading. The comedian and wife Elle Key turned the Eras Tour into a date night in Toronto, Canada . He tweeted in November 2024, "And the night is just getting started! So excited to be at my first @taylorswift13 concert." Billy Joel "Our family attended the Taylor Swift concert at Hard Rock Stadium in Miami where Billy Joel/Elton John’s ‘Face to Face’ concert previously held the seating record," he wrote on Instagram. "Taylor’s second concert at Hard Rock Miami set a new record and ushered in a new era at Hard Rock Stadium. We were so happy to be a part of this record-breaking concert! Plus, we got to celebrate with her mama. Celebrating someone’s success does not negate your own. She is showing our girls all that is possible. Onward and upward." Ashley Tisdale "My little swiftie," the High School Musical alum wrote on October 2024. "Safe to say Jupiter loved her first concert." Travis Kelce, Prince William, Princess Charlotte & Prince George Taylor made her relationship with Travis Instagram official June 21, 2024, with the help of the royal family as they all joined her backstage at her concert in Wembley Stadium in London. Prince William, Princess Charlotte & Prince George Taylor also took another selfie with the royal family at her Wembley show. Nicola Coughlan, Cara Delevingne & Jonathan Van Ness The trio united in the VIP tent in London on June 21, 2024. Leslie Mann & Jonathan Van Ness The Knocked Up actress also hung out with the Queer Eye alum at the Wembley concert. Travis Kelce & Jonathan Van Ness The NFL star was a true London Boy at Wembley Stadium with the Queer Eye star. Jonathan Van Ness & Nicola Coughlan Dearest reader, how adorable is this friendship? Gayle King & Channing Tatum The two bumped into each other at one of the singer's shows at SoFi Stadium in Inglewood, Calif. in August 2023. Channing Tatum The Step Up star showcased his dance moves. Christina Milian The "Dip It Low" singer and her teen daughter Violet were in a lavender haze at Taylor's Paris show in May 2024. Jessica Capshaw The Grey's Anatomy actress attended the Eras Tour in France in May 2024, captioning this pic with the Midnights lyric, "Cause we were in Paris." Travis Kelce & Rita Ora "It’s fair to say Sydney always delivers," Rita Ora captioned Instagram photos from Taylor's Feb. 23 show, including a snap with Travis Kelce . "Or shall we say our TayTay @taylorswift always delivers!” Taika Waititi, Taylor Swift & Rita Ora Taylor's dad Scott Swift delivered an epic photobomb. Katy Perry "Got to see an old friend shine tonight," Katy Perry captioned footage on Instagram from the Feb. 23 concert. Tom DeLonge & Rebel Wilson The Blink-182 rocker—whose band was playing near Taylor's Sydney venue on the same day—and the Pitch Perfect alum hung out in the VIP tent. The Oscar winner captioned the moment with friends in Mexico City, "Spamming u w really good @taylorswift Eras Tour content." The Pretty Little Liars star attended with friends Morgan Pesante , Katie Greenthal and Claire Leahy . "Omg??? @taylorswift putting on a show that was so good I can't even process," she wrote. "Nostalgic, empowering, and sparkly." The "Bad at Love" singer got in the spirit by making friendship bracelets to trade with fans during the last Los Angeles show. Mariska Hargitay & Savannah Guthrie "Still in the afterglow of the most magical night," the Law & Order: Special Victims Unit star wrote on Instagram Aug. 9 after a bejeweled night out in L.A. "Deepest gratitude to @taylorswift for your poetry and wisdom. You inspire us and connect us to our #delicate tenderness, joy, hope and strength—and most of all, our wish to live and love courageously." Sharing pics from an L.A. show, Chris Olsen quoted the T.Swift lyrics in his caption, "I DON'T KNOW HOW IT GETS BETTER THAN THIS." "Eras tour (Dylan's version)," the influencer captioned fits of her rocking a Stella McCartney outfit. "@taylorswift you are a goddess best night ever." Spencer Pratt & Heidi Montag The Hills stars filled a blank space in their calendar with a date night in Los Angeles at the Eras Tour. Heidi Montag captioned their pics, "This was the concert of a lifetime! Legendary! Thank you for the tickets @taylorswift." Jessica Alba & Cash Warren "@taylorswift with the fam," Jessica Alba wrote, "what a show!" She and husband Cash Warren celebrated their love story by taking their kids Honor , Haven and Hayes . The Mad Max star danced to "Shake It off" with her kids August and Jackson . "Thank you for the best birthday ever @taylorswift!!!" she wrote. "We had such a great f--king time." Paula Abdul & Vince Vaughn "What a SHOW," Paula Abdul wrote while posting for a photo with Vince Vaughn and Taylor's parents Scott and Andrea Swift in Los Angeles. James Kennedy, Paula Abdul, Scheana Shay & Ally Lewber The Vanderpump Rules stars made their wildest dreams come true on the floor with Paula. The "No One singer" attended the Aug. 5 show at SoFi Stadium in Los Angeles with her 8-year-old son Genesis . The actress attended one of Swift's shows at SoFi Stadium in Los Angeles with Anastasia Beverly Hills cosmetics founder Anastasia Soare and her daughter, Claudia .

NoneNonePIAA officials postpone PIAA football quarterfinal between Westinghouse, Bishop Guilfoyle By: Friday, November 22, 2024 | 3:58 PM Chaz Palla | TribLive Westinghouse's Lloyd Penn dives for extra yardage past Allderdice's Darryl Stong during the City League championship Oct. 26, 2024 at Cupples Stadium. Because of inclement weather, PIAA officials on Friday moved the game to 1...

The following is a transcript of an interview with Rep. Mike Turner, Republican of Ohio, on "Face the Nation with Margaret Brennan" that aired on Dec. 8, 2024. MARGARET BRENNAN: We're joined now by the Chairman of the House Intelligence Committee, Ohio, Congressman Mike Turner. Just a stunning turn of events within such a short period of time. The US doesn't have a diplomatic presence inside of Syria. Our visibility is a little limited here. What is it that you think Americans need to know about this turn of events? REP. MIKE TURNER: Margaret, that was an excellent report, because you certainly laid the groundwork of this has been an incredibly brutal civil war with hundreds of thousandss of people dying, including the use of chemical weapons. And of course, reminding people that the Obama administration had said this would be a red line, that we would use military force to stop the use of chemical weapons, then failing to do so. This is a Islamic militia that has risen up and has continued and now is successfully toppling the Assad regime. As your report indicated, it's al Qaeda in its origins, but it opposes ISIS. It is Turkish-backed. This is a blow to Iran, a blow to Russia. We're seeing what is likely a disintegration in Syria. The big questions will be, what does this mean for the US? What does it mean for Iran, Russia, the neighbors of Israel and Jordan, which are strong allies of the United States? MARGARET BRENNAN: So you mentioned there, and we showed the picture of Abu Muhammad al-Jolani. He is the leader of Hayat Tahrir al-Sham, people call HTS. You're going to hear a lot about that in the coming days and weeks, the rebel group that appears to be taking control. But they are working also with the Prime Minister. The United States government has a ten million bounty on the head of Jolani. Do you think the United States still should keep that? Should Americans be concerned that this will mean something in terms of impact for terror threats to the United States. REP. TURNER: This is a terrorist organization and group, but this is not going to be just a passing of power and authority. It could be. We'll have to, obviously, watch that. You know, one of the things that we do see here, though, is this is a diplomatic failure with respect to the United States and Turkey. You know, the U.S. has troops in Syria. This is on the border of Turkey. Turkey is a NATO ally. The United States is working with the Kurds. This really could have been an opportunity for the United States to work to try to resolve the issue between the Kurds, Turkey and the United States and working with Turkish interests in Syria. Hopefully this could be an opportunity where there could be a diplomatic support there that hopefully could have- help in this transition in Syria. MARGARET BRENNAN: There are 900 US troops in Syria in the South. Donald Trump in 2019 pulled US troops out of northern Syria, abandoning our allies there. Do you believe he will stand by the 900 US troops that remain there? Or should he consider pulling them out when he takes office? REP. TURNER: Well I think, you know, one of the things that Donald Trump will make clear is, is that any any threat to us, troops will be unbelievably responded to. So everyone should understand, absolutely, the United States troops are to be secure. The second thing is, is he does absolutely support the Kurds and that he's going to look for a diplomatic solution. I think there will be an assessment as to whether or not those troops should remain. But it's, you know, I think here there is an opportunity for the parties, especially now that Iran and Russia's roles are going to be domin- diminished. They have been brutal in their support with Assad, the hundreds of thousands of people, including use of chemical weapons that have been killed, have been under the Russian influence there. Russia still has two bases, a naval and air force base there that are going to be, you know, both at risk for Russia, but also a risk to the population of Syria because they could- they have been used before to attack the Syrian population. We'll have to see what Russia does there. But this is going to be an area that's going to be highly volatile and in transition. MARGARET BRENNAN: And no idea where Bashar Al Assad might have fled to? REP. TURNER: No, not at this time. MARGARET BRENNAN: I want to ask you, since we're talking about the incoming administration, Donald Trump has chosen Tulsi Gabbard, the former Congresswoman, a former Democrat, now Republican, to be the Director of National Intelligence, overseeing 18 intelligence agencies. She not only went and met with Assad, she publicly doubted high confidence assessments by U.S. intelligence that he did what we showed you pictures of him doing, using chemical weapons there. Do you trust that she could actually represent the intelligence community, lead it and be trusted to brief the Commander in Chief? REP. TURNER: Well, I obviously differ in a great deal in a number of areas with both her judgment and and her background and experience, but what I do trust is the– MARGARET BRENNAN: –You're smiling when you're saying this– REP. TURNER: The Senate is the Senate process, and I think this- the senators are going to put her through a process. She has been nominated. She will go through the process, and I think there will be significant debate and evaluation. I think– MARGARET BRENNAN: –You don't think she'll be confirmed?-- REP. TURNER: –that Donald Trump has put together in his last term, and I think he will in this term, a great national security team. I think CIA director, Radcliffe, I think Mike Waltz as National Security Director, are both great examples of people who are going to be foundational. I think you're going to see a great national security team. MARGARET BRENNAN: Well, this is a community that you also have oversight of, so you may not vote in the Senate, but it sounds like she doesn't have your confidence. What about Pete Hegseth to run the Pentagon at a time of global instability? REP. TURNER: Yeah, I think the Chairman of the Armed Services in the Senate made a great statement. He said, we certainly support the process, and he has his support going through the process, and we'll have to see how that goes through. One thing that is absolutely clear is that the Pentagon needs reformed. We are not keeping pace with what Russia and China are doing in advanced weapon systems. At the same time, we're seeing the weapon systems of advanced technology that are being utilized on the battlefield of Ukraine, and our acquisition systems and our accounting systems, our spending systems are not working at the Pentagon– MARGARET BRENNAN: -That requires experience– REP TURNER: –We need reform. We need reform. Someone has to be able to lead that, and that's going to be the debate in the Senate. MARGARET BRENNAN: I love when I ask Congresspeople, and they just keep reminding me that they don't sit in the Senate and don't want to comment. I sense some some uncertainty there on your part, but I don't want to put words in your mouth. I want to ask you though about what is ticking down in Congress right now, and that is something there's a scramble at the end of this year to get a bunch of work done. Your Democratic colleague in the Senate, Mark Warner, said "it is an urgent priority to address cybersecurity gaps in these final weeks." Is it a priority for you to do something because of this massive breach by China, of U.S. Telecom? REP. TURNER: You know, one thing that's- it's very disappointing, and we've seen from this administration, this this malaise of this stasis of where they're unable to move as a result of the president unable to make a decision. Here we have this massive breach, this hack that has occurred from China, but we're hearing nothing from the president himself, no action from this administration as to what their- what consequences that will be. This is not- doesn't need just a technological fix. This needs also a diplomatic fix, a nation to nation, consequences to China– MARGARET BRENNAN: –What would consequences look like? REP. TURNER: Now in the Obama administration, in the Obama administration, China hacked the personnel management system of the US government, and there were no consequences, and now we're seeing China hack the entire system of the nation. There needs to be consequences. They can be economic. They can be in a number of ways. But right now we have zero, we have nothing coming out of the administration. What need to be talking about is not technologically how do we fix this? But how do we address, which is what Donald Trump is doing, is coming in and saying China is our most, gravest threat. How do we address the fact that China is aggressively attacking the United States, and they're doing that in our telecom? MARGARET BRENNAN: Question for the incoming administration to pick that up. Thank you, Chair Turner. "Face the Nation" will be back in a minute. Stay with us.2 cheap dividend stocks to kickstart your 2025 portfolio - Finbold - Finance in Bold

The new, 12-team College Football Playoff brings with it a promise to be bigger, more exciting, more lucrative. Perfect or 100% fair? Well, nobody ever believed that. The first expanded playoff bracket unveiled Sunday left a presumably deserving Alabama team on the sideline in favor of an SMU squad that finished with a better record after playing a schedule that was not as difficult. It ranked undefeated Oregon first but set up a possible rematch against Ohio State, the team that came closest to beating the Ducks this year. It treated underdog Boise State like a favorite and banged-up Georgia like a world beater at No. 2. It gave Ohio State home-field advantage against Tennessee for reasons it would take a supercomputer to figure out. It gave the sport the multiweek tournament it has longed for, but also ensured there will be plenty to grouse about between now and when the trophy is handed out on Jan. 20 after what will easily be the longest college football season in history. All of it, thankfully, will be sorted out on the field starting with first-round games on campuses Dec. 20 and 21, then over three succeeding rounds that will wind their way through traditional bowl sites. Maybe Oregon coach Dan Lanning, whose undefeated Ducks are the favorite to win it all, put it best when he offered: "Winning a national championship is not supposed to be easy.” Neither, it turns out, is figuring out who should play for it. Alabama comes up short in the bracket’s biggest debate The Big Ten will lead the way with four teams in the tournament, followed by the SEC with three and the ACC with two. The lasting memory from the inaugural bracket will involve the decision that handed the ACC that second bid. Alabama of the SEC didn't play Saturday. SMU of the ACC did. The Mustangs fell behind by three touchdowns to Clemson before coming back to tie. But they ultimately lost 34-31 on a 56-yard field goal as time expired. “We were on pins and needles,” SMU coach Rhett Lashley said. “Until we saw the name ‘SMU’ up there, we were hanging on the edge. We're really, really happy and thankful to the committee for rewarding our guys for their total body of work." The Mustangs only had two losses, compared to three for the Crimson Tide. Even though SMU's schedule wasn't nearly as tough, the committee was impressed by the way the Mustangs came back against Clemson. “We just felt, in this particular case, SMU had the nod above Alabama,” said Michigan athletic director Warde Manuel, the chairman of the selection committee. “But it’s no disrespect to Alabama’s strength of schedule. We looked at the entire body of work for both teams.” Crimson Tide AD gracious, but looking for answers Alabama athletic director Greg Byrne was gracious, up to a point. “Disappointed with the outcome and felt we were one of the 12 best teams in the country,” he said on social media. He acknowledged — despite all of Alabama’s losses coming against conference opponents this season — that the Tide’s push to schedule more games against teams from other major conferences in order to improve its strength of schedule did not pay off this time. “That is not good for college football," Byrne said. Georgia, Boise State and Arizona State join Oregon with first-round byes Georgia, the SEC champion, was seeded second; Boise State, the Mountain West champion, earned the third seed; and Big 12 titlist Arizona State got the fourth seed and the fourth and final first-round bye. All will play in quarterfinals at bowl games on Dec. 31-Jan. 1. Clemson stole a bid and the 12th seed with its crazy win over SMU, the result that ultimately cost Alabama a spot in the field. The Tigers moved to No. 16 in the rankings, but got in as the fifth-best conference winner. Automatic byes and bids made the bracket strange The conference commissioners' idea to give conference champions preferable treatment in this first iteration of the 12-team playoff could be up for reconsideration after this season. The committee actually ranked Boise State, the Mountain West Champion, at No. 9 and Big 12 champion Arizona State at No. 12, but both get to skip the first round. Another CFP guideline: There’s no reseeding of teams after each round, which means no break for Oregon. The top-seeded Ducks will face the winner of Tennessee-Ohio State in the Rose Bowl. Oregon beat Ohio State 32-31 earlier this year in one of the season’s best games. What the matchups look like No. 12 Clemson at No. 5 Texas, Dec. 21. Clemson is riding high after the SMU upset, while Texas is 0-2 against Georgia and 11-0 vs. everyone else this season. The winner faces ... Arizona State in the Peach Bowl. Huh? No. 11 SMU at No. 6 Penn State, Dec. 21. The biggest knock against the Mustangs was that they didn't play any big boys with that 60th-ranked strength of schedule. Well, now they get to. The winner faces ... Boise State in the Fiesta Bowl. Yes, SMU vs. Boise was the quarterfinal we all expected. No. 10 Indiana at No. 7 Notre Dame, Dec. 20. Hoosiers coach Curt Cignetti thought his team deserved a home game. Well, not quite but close. The winner faces ... Georgia in the Sugar Bowl. The Bulldogs got the No. 2 seed despite a throwing-arm injury to QB Carson Beck. But what else was the committee supposed to do? No. 9 Tennessee at No. 8 Ohio State , Dec. 21. The Buckeyes (losses to Oregon, Michigan) got home field over the Volunteers (losses to Arkansas, Georgia) in a matchup of programs with two of the biggest stadiums in football. The winner faces ... Oregon in the Rose Bowl. Feels like that matchup should come in the semifinals or later. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

PIAA officials postpone PIAA football quarterfinal between Westinghouse, Bishop Guilfoyle

South Korea President Yoon banned from foreign travel as leadership crisis deepensNone

FORT WORTH, Texas (AP) — Wade Taylor IV scored 19 points, Zhuric Phelps hit a go-ahead 3-pointer during an 11-0 run and finished with 12 points, and 22nd-ranked Texas A&M beat Texas Tech 72-67 on Sunday in the first meeting of the former conference rivals since 2012. Read this article for free: Already have an account? To continue reading, please subscribe: * FORT WORTH, Texas (AP) — Wade Taylor IV scored 19 points, Zhuric Phelps hit a go-ahead 3-pointer during an 11-0 run and finished with 12 points, and 22nd-ranked Texas A&M beat Texas Tech 72-67 on Sunday in the first meeting of the former conference rivals since 2012. Read unlimited articles for free today: Already have an account? FORT WORTH, Texas (AP) — Wade Taylor IV scored 19 points, Zhuric Phelps hit a go-ahead 3-pointer during an 11-0 run and finished with 12 points, and 22nd-ranked Texas A&M beat Texas Tech 72-67 on Sunday in the first meeting of the former conference rivals since 2012. Phelps’ 3 with 7 1/2 minutes left made it 54-52 and put the Aggies (8-2) ahead to stay. His step-back jumper after hard contact with Tech’s Kevin Overton capped the game-turning spurt. Jace Carter scored 13 of his 16 points in the first half as Texas A&M won its fourth straight game. Chance McMillian had 23 points with five 3s for Tech (7-2). Overton scored 14 of his 17 points before halftime, when he hit four 3s. Takeaways Texas Tech played its second game in a row without leading scorer and rebounder JT Toppin (18.6 ppg/11 rpg) because of what the school said is a lower-body injury for the 6-foot-9 forward. Texas A&M made all eight of its free throws in the final 27 seconds, four by Taylor, while Tech made three 3s in the final minute. Key moment Texas A&M led 23-12 in the first half on a 3-pointer by Carter, that opened a 45-second exchange of two 3s each by he and Overton. The second 3 by Overton started a 9-0 run that got the Red Raiders within 26-24. Key stat Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. The Aggies and Red Raiders played at least twice annually between 1958-2012 while members of the old Southwest Conference and then the original Big 12 before Texas A&M went to the SEC. Their first non-conference meeting since 1953 was at Dickies Arena, a neutral site. Up next Texas A&M plays No. 8 Purdue in Indianapolis on Sunday. Texas Tech hosts Oral Roberts on Dec. 16. ___ Get poll alerts and updates on the AP Top 25 all season. Sign up here. AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball Advertisement AdvertisementThe transition to lower-carbon energy will require a massive investment. According to Goldman Sachs , the world needs to invest an estimated $3 trillion annually through the end of the decade to support its goals of reaching net zero carbon emissions in the coming decades. That massive investment spans multiple opportunities, including renewable energy, electricity grids, and increased electrification. One company that is absolutely critical to building this infrastructure is Quanta Services ( PWR -2.26% ) . It's the industry leader in providing specialized infrastructure solutions. Here's a closer look at this crucial infrastructure stock . Digging into Quanta Services Quanta Services provides specialized infrastructure solutions to the utilities , renewable energy , technology, communications, pipeline , and energy industries. Its client list is a who's who of industry leaders in those respective sectors, including Duke Energy , NextEra Energy ( NEE -0.36% ) , Verizon , and Enbridge . It helps these companies design, install, repair, and maintain their infrastructures. While the company's services span several infrastructure assets, about three-quarters of its revenues come from utilities and renewable energy developers. That puts it in a strong position to capitalize on the growing total addressable market opportunity for infrastructure related to the transition to lower-carbon energy. For example, investor-owned U.S. electric utilities (e.g., Duke Energy and NextEra) expect to incur $186.4 billion in capital expenses to maintain and expand their electricity transmission and distribution systems and power-generating capabilities this year. They will spend $51 billion on power-generation projects, with 65% of that capital going toward renewable energy. That number should rise significantly in the coming years. Forecasters estimate that the U.S. will deploy 375-450 gigawatts (GW) of new renewable and storage capacity over the next seven years. That's three times more capacity than the country deployed over the last seven (140 GW). Customers like NextEra Energy are driving this acceleration (it expects to more than double its renewables and storage capacity from 38 GW today to 81 GW by 2027). NextEra Energy is also investing capital to build out transmission lines and maintain and expand its electric utility operations in Florida. That's just one opportunity in one country. Quanta Services operates across multiple industries and countries, providing customers with a growing array of services . The strong performance should continue Increasing infrastructure investment is driving strong growth for Quanta Services this year. It delivered another quarter of double-digit growth in the third quarter. Its revenue rose from $5.6 billion to $6.5 billion, while its adjusted earnings increased from $2.24 per share to $2.72. It also generated $539.5 million in cash flow, pushing its year-to-date total to nearly $1.4 billion (with almost $980 million in free cash). That strong performance has helped drive a more than 50% increase in its stock price this year. Quanta Services is in a strong position to continue growing. It ended the third quarter with a record $34 billion of projects in its backlog. That gives it a lot of confidence in its continued growth. "We believe we are well positioned to achieve another year of double-digit earnings-per-share growth in 2025 due to increasing demand for our services, strong execution of our strategic plan and capital deployment opportunities," stated CEO Duke Austin in the third-quarter earnings press release. The company has been enhancing its ability to continue growing and capture a greater share of the massive opportunity it sees ahead for energy transition investments. Quanta has made several acquisitions and investments over the past year to bolster its capabilities, including acquiring Cupertino Electric (a premier electrical infrastructure solution provider) and investing in Hybar (a company building a technologically advanced scrap metal recycling rebar mill ). It has also invested capital back into its business to drive additional organic growth. The company believes these investments will enable it to deliver solid revenue and earnings growth over the long term. A potentially compelling way to invest in this massive megatrend The world will invest trillions of dollars in building lower-carbon energy infrastructure in the coming years. That trend plays right into the strengths of Quanta Services, which is a leading provider of specialized infrastructure solutions to utilities and renewable energy developers. It should drive continued healthy growth for the company, making it a potentially compelling way to invest in this massive megatrend.

Previous:
Next: 4 mnl